On January 6, 2025, Candid Therapeutics, Inc., a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases, announced an agreement with WuXi Biologics under which Candid will have exclusive global rights to a preclinical trispecific T-cell engager developed by WuXi Biologics’ proprietary universal multispecific antibody platform, WuXiBody™. Candid plans to complete IND enabling studies to enable first-in-human studies in the first half of 2026. Wilson Sonsini Goodrich & Rosati advised Candid on technology transactions and patent matters related to the transaction.

Under the terms of the agreement, WuXi Biologics is entitled to obtain an upfront payment and development and sales milestones totaling up to $925 million, as well as royalties.

The Wilson Sonsini team advising Candid on the transaction includes:

Technology Transactions
Norm Hovijitra

Patents and Innovations
Laurie McNamara
Mike Hostetler
Yingchun Ni
Jennifer Floyd

For more information, please see the companies’ news release. Additional details are available on Fierce Biotech.